Favorable Government Policies and a Surge in the NHL has Propelled the Growth of the Rituximab Market in the North America Region!
- Vikas Kumar
- July 12, 2023
- HEALTHCARE, NEWS
- 0 Comments
The North American rituximab market is expected to grow at a significant rate during the forecast period, due to the increasing prevalence of hematological disorders and the growing awareness about the benefits of rituximab. Additionally, the increasing adoption of advanced therapy medicinal products (ATMPs) and the increasing number of clinical trials for the treatment of hematological disorders in the region are also expected to boost the market growth.
Access sample report (including graphs, charts, and figures): https://univdatos.com/report/rituximab-market/get-a-free-sample-form.php?product_id=40712
Further, the North America Rituximab Market is expected to grow at a strong CAGR of 14% during the forecast period (2023-20230). In the US, non-Hodgkin lymphoma (NHL) is a relatively common cancer that affects approximately 4% of all cancer cases. As of March 2022, the American Cancer Society estimates that approximately 80,470 people, including both adults and children, will be diagnosed with NHL. The lifetime risk of developing NHL is estimated to be 1 in 42 for men and 1 in 52 for women, indicating that the growth of the target population is likely to contribute to regional growth. Moreover, favorable government approvals are also driving the growth of the market in the region. For instance, in June 2022, US FDA granted approval to Riabni, a biosimilar to Rituxan, in combination with methotrexate for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. RIABNI is already approved for the treatment of adult patients with Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also called Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA).
- FIG. 1 North America Rituximab Market Revenue (2020-2030)- USD Mn
For a detailed analysis of the Global Rituximab Market browse through https://univdatos.com/report/rituximab-market/
Based on the route of administration, the market is segmented into subcutaneous, intravenous, and parenteral. The intravenous (IV) category held a significant share of the market in 2022 as IV rituximab is administered through a vein, making it a quick and efficient way to deliver the drug to the patient’s body. Moreover, IV rituximab is absorbed into the bloodstream quickly, allowing it to begin working faster than other forms of rituximab. Thus, these factors are driving the growth of the segment in the forecast period.
By application, the market is categorized into non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and others. The non-hodgkin lymphoma is anticipated to grow with significant CAGR during the forecast period. According to the World Health Organization, an estimated 5,000,000 new cases of non-Hodgkin’s lymphoma (NHL) were diagnosed in 2020. In the United States, NHL accounts for nearly 4% of all cancer cases. The rising incidence of NHL is expected to drive significant demand for rituximab biosimilars in the market over the forecast period.
Based on distribution channel, the market is segmented into hospital pharmacy, online pharmacy, and others. The hospital pharmacy held a dominant share of the market in 2022 owing to the increasing patient population, and growing focus on patient safety. Moreover, as the number of prescriptions filled by hospitals continues to rise, so too will the demand for hospital pharmacies to manage and dispense these medications, thus having a positive impact on segmental growth.
Global Rituximab Market Segmentation
Market Insight, by Route of Administration
- Subcutaneous
- Intravenous
- Parenteral
Market Insights, by Application
- Non-Hodgkin Lymphoma
- Chronic Lymphocytic Leukemia
- Rheumatoid Arthritis
- Others
Market Insights, by Distribution Channel
- Hospitals Pharmacy
- Online Pharmacy
- Others
Market Insights, by End User
- Hospitals
- Clinics
- Others
Market Insight, by Region
- North America
- U.S.
- Canada
- Rest of North America
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- North America
- China
- Japan
- India
- Rest of North America
- Rest of the World
Top Company Profiles
- Pfizer Inc.
- Amgen Inc.
- Viatris Inc.
- F. Hoffmann-La Roche
- Dr. Reddy’s Laboratories Ltd.
- Zydus Group
- Novartis AG
- Teva Pharmaceutical Industries Ltd.
- Hetero
- BioXpress Therapeutics SA
